[ad_1]
Abu DhabiUnited Arab Emirates, December 20, 2022 /PRNewswire/ — Building on Department of Health’s Ongoing Efforts — Abu Dhabi (DoH) lead the way Abu Dhabi healthcare ecosystem, AstraZenecaa science-led biopharmaceutical company and one of the top ten global biopharmaceutical companies, signed a strategic cooperation agreement with artificial intelligence-driven healthcare company G42 Healthcare to locally manufacture innovative drugs in China Abu Dhabi. The binding agreement focuses on cooperation in four key areas, including localization of innovative industries, research and development, innovation and sustainable development on a global scale. The agreement cements the emirate’s position as a hub for life sciences research and innovation and is the latest in a series of long-term partnerships with key players in the pharmaceutical industry.
The agreement is in line with the National Industrial and Advanced Technology Strategy and the Make it in the Emirates initiative launched by the Ministry of Industry and Advanced Technology to enhance the UAE’s business environment and status as an attractive destination for local and global industrial investment By. It also supports the growth and competitiveness of national industries, the innovation and adoption of advanced technologies, and the UAE’s position as a global hub for future industries.
In the presence of His Excellency Abdulla bin Mohammed Al Hamed, Chairman of the Ministry of Health, and His Excellency Pascal Soriot, Executive Director and CEO of AstraZeneca, HE Dr. Jamal Mohammad KabiDeputy Minister of Health, Peng XiaoCEO of the G42 Group, confirmed the partnership by signing a binding agreement Ashish KoshiG42 Healthcare CEO and Palin InchesuRegional Vice President, middle East and Africa at AstraZeneca.
The landmark signing was witnessed by a distinguished delegation representing various government agencies, including the Ministry of Health and Prevention, the Ministry of Industry and Advanced Technology, and the Abu Dhabi Investment Office.
Creating Transformative Shifts in Traditional Healthcare Paradigms Abu Dhabi, the agreement contributes to the ongoing efforts to build a competitive knowledge-based economy by unlocking the potential of the UAE’s national capabilities.reflecting Abu Dhabi Strong healthcare infrastructure, G42 Healthcare and AstraZeneca outline Abu Dhabi.
partnership factor Abu Dhabi Industrial strategy to double the size of manufacturing by 2031.Essentially, the agreement will expand the Abu Dhabi footprint in life science research and development and enabling innovation across all healthcare sectors. All parties will work closely together to boost exports and develop cutting-edge science and activities to support the delivery of life-changing medicines to Emirati patients. Based on international best practice, the partnership aims to develop sustainable solutions for healthcare transformation while achieving a balance between economic growth and sustainability.
The agreement is in line with the goals of the Make it in the Emirates campaign, and the advantages and incentives that the UAE offers to the industrial sector, including a supportive legislative framework, flexible financing solutions, world-class infrastructure and an advanced transport network. These incentives are aimed at creating investment opportunities, strengthening national and international investor partnerships, increasing efficiency, improving product quality and its global competitiveness.
As the UAE embarks on an ambitious journey over the next 50 years, the agreement cements Abu Dhabi Positioned as a hub for life sciences research and innovation, the collaboration is the latest in a series of long-standing partnerships with key players in industries including the pharmaceutical industry. By overseeing similar strategic partnership agreements, the Ministry of Health seeks to play a key role in the UAE’s knowledge economy by creating unique jobs that require highly skilled workers and human capital. Under the “We the UAE 2031” plan, the agreement is expected to attract the best minds in the field of medicine, while supporting the UAE’s entry into the top 10 countries in healthcare. It will also help increase the contribution of the industrial sector to GDP and support the growth of non-oil exports.
While commenting, Dr. Ho Jamal Mohammad KabiUndersecretary for Health – Abu Dhabisaid: “Under the direction of the UAE’s wise leadership, our country continues to strongly support research and innovation as part of our ongoing efforts to support the healthcare industry. Abu Dhabi With the support of our international partners, we continue to lead pivotal research exploring the sustainability and resilience of the global healthcare industry while ensuring quality healthcare for patients…”
PhD alcabi Added: “Localization and manufacturing of pharmaceuticals Abu Dhabi A true translation of our ‘Made in UAE’ campaign – the cornerstone of sustainability in all industries.International appetite and investment opportunities in the biopharmaceutical and healthcare value chain are emerging due to the industry’s strong growth potential Abu Dhabi. Research in all its forms remains a core driver in achieving all of our ambitions as we continue to build on Abu Dhabi As a leader in innovative healthcare and life sciences. While we partner with globally renowned pharmaceutical institutions, we aim to maintain the rapid development of a pioneering healthcare model powered by an agile and futuristic ecosystem. “
Sameh El FangaryGCC cluster chair and Pakistan at AstraZenecasaid: “AstraZeneca is honored to be a long-term and trusted partner in the UAE, bringing innovative healthcare to the region, and we appreciate it Abu Dhabi Ambitions to become a regional life sciences hub. We are now taking our comprehensive existing partnership with G42 Healthcare to new heights, accelerating collaboration on local manufacturing, research, innovation and sustainable development. I believe this partnership will greatly facilitate the development of a sustainable health ecosystem that can transform patient outcomes. “
Partnership further established Abu Dhabi As a powerhouse of medical research and innovation on the international stage. In 2021, the emirate’s capacity to develop scientific and clinical research has doubled – with more research projects in the year than in the previous five years. Serving as a unified platform to support global R&D efforts to fight the virus, the Ministry of Health’s Covid-19 Research Registry has received more than 376 scientific papers in 2021, with 67 facilities in Abu Dhabi licensed for healthcare research. Today, more than 400 clinical research trials are underway in the UAE.
Ashish KoshiChief Executive Officer, G42 Healthcare said: “We are confident in the potential of our continued collaboration with AstraZeneca, which has a strong commitment to the UAE healthcare industry and is poised to become a global hub for life sciences research and innovation. This strategic collaboration will accelerate innovation in local manufacturing , and allows us to explore greater possibilities in our clinical research to deliver life-changing treatments to patients in the UAE and across the region. At the heart of this partnership is that we will foster sustainable manufacturing capabilities and drive innovation globally , as together we envision better healthcare for all.
photo – https://mma.prnewswire.com/media/1972157/The_Department_of_Health_Abu_Dhabi_G42.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/astrazenca-g42-healthcare-enter-strategic-partnership-to-manufacture-pharmaceutical-products-in-abu-dhabi-301707295.html
Source Department of Health – Abu Dhabi
[ad_2]
Source link